Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Angel Pharma to Start China Trial of ITK Inhibitor for Lymphoma

publication date: Oct 26, 2021

Angel Pharma, a Jiaxing-Los Angeles company, was approved to start China clinical trials of a small molecule ITK inhibitor in patients with relapsed/refractory T-cell lymphomas. CPI-818, the first ITK inhibitor in clinical development, is designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase) without affecting related kinases such as RLK and BTK. Corvus Pharma discovered the drug. One year ago, Corvus formed Angel as a China JV with $106 million in original capital and China rights to three of its assets, including CPI-818. More details....

Stock Symbol: (NSDQ: CRVS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.